The problem
Drug discovery takes years per design cycle; AI drug designs need fast real-world lab data to improve
What they do
AI-driven, vertically integrated lab designing peptide drugs, starting with sleep
Traction Preclinical: first sleep candidate (CAPABLE-002) entering safety studies; no revenue
Hiring trend
- Open roles
- 22
- Ops roles
- 1
- Headcount
- ~10-15
Out of stealth Jul 2026; ~20 open roles since Aug; team ~9 on LinkedIn, lab 2K → 22.5K sq ft
Hiring in
- San Francisco
Funding
- Last round
- $38M
- Stage
- Seed
- Date
- Oct 2026
Led by Cathay Innovation, Abstract Ventures
- Hiring+1.522 open roles on the live job board (10–29 roles = +1.5)
- Funding recency+1.5Seed · $38M, Oct 2026 (this month): 6 months or less = +1.5
- Traction0No growth signal counted: Preclinical: first sleep candidate (CAPABLE-002) entering safety studies; no revenue
- Red flags0None found in the last 24 months
- Total3.01.5 + 1.5 + 0 − 0 = 3.0 → Warm-up
Stealth rule: just out of stealth, so it starts in Warm-up whatever the score (Steady by score alone).
Distance (Unproven) is a separate read on how long the lead can last. It doesn't change the score.
Distance
Unproven · edge: learns from use
Bets on a proprietary design-synthesize-test data loop; just out of stealth with only preclinical programs, so no proof yet that its drugs work in humans.
Sources: Capable: Fall update, $38M seed and new SF lab (Oct 2026) ↗ · Harpoon Ventures: Capable company profile ↗
Open ops roles · 1
Last checked Oct 25, 2026